Logo image of KURA

KURA ONCOLOGY INC (KURA) Stock Fundamental Analysis

USA - NASDAQ:KURA - US50127T1097 - Common Stock

9.05 USD
+0.69 (+8.25%)
Last: 9/26/2025, 8:06:16 PM
8.8105 USD
-0.24 (-2.65%)
After Hours: 9/26/2025, 8:06:16 PM
Fundamental Rating

3

KURA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 538 industry peers in the Biotechnology industry. The financial health of KURA is average, but there are quite some concerns on its profitability. KURA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KURA has reported negative net income.
KURA had a positive operating cash flow in the past year.
In the past 5 years KURA always reported negative net income.
KURA had negative operating cash flow in 4 of the past 5 years.
KURA Yearly Net Income VS EBIT VS OCF VS FCFKURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

KURA has a better Return On Assets (-28.89%) than 67.66% of its industry peers.
The Return On Equity of KURA (-64.54%) is better than 60.04% of its industry peers.
Industry RankSector Rank
ROA -28.89%
ROE -64.54%
ROIC N/A
ROA(3y)-28.89%
ROA(5y)-24.99%
ROE(3y)-37.6%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
KURA Yearly ROA, ROE, ROICKURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KURA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KURA Yearly Profit, Operating, Gross MarginsKURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

6

2. Health

2.1 Basic Checks

KURA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KURA has more shares outstanding
KURA has more shares outstanding than it did 5 years ago.
KURA has a better debt/assets ratio than last year.
KURA Yearly Shares OutstandingKURA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
KURA Yearly Total Debt VS Total AssetsKURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -0.90, we must say that KURA is in the distress zone and has some risk of bankruptcy.
KURA's Altman-Z score of -0.90 is in line compared to the rest of the industry. KURA outperforms 57.06% of its industry peers.
The Debt to FCF ratio of KURA is 0.08, which is an excellent value as it means it would take KURA, only 0.08 years of fcf income to pay off all of its debts.
KURA's Debt to FCF ratio of 0.08 is amongst the best of the industry. KURA outperforms 96.65% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that KURA is not too dependend on debt financing.
KURA has a Debt to Equity ratio (0.02) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.08
Altman-Z -0.9
ROIC/WACCN/A
WACC9.95%
KURA Yearly LT Debt VS Equity VS FCFKURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 6.16 indicates that KURA has no problem at all paying its short term obligations.
KURA's Current ratio of 6.16 is fine compared to the rest of the industry. KURA outperforms 64.13% of its industry peers.
A Quick Ratio of 6.16 indicates that KURA has no problem at all paying its short term obligations.
The Quick ratio of KURA (6.16) is better than 64.68% of its industry peers.
Industry RankSector Rank
Current Ratio 6.16
Quick Ratio 6.16
KURA Yearly Current Assets VS Current LiabilitesKURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

KURA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.35%.
EPS 1Y (TTM)-1.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

KURA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.31% yearly.
The Revenue is expected to grow by 151.48% on average over the next years. This is a very strong growth
EPS Next Y-27%
EPS Next 2Y-13.83%
EPS Next 3Y-8.55%
EPS Next 5Y24.31%
Revenue Next Year895.54%
Revenue Next 2Y404.04%
Revenue Next 3Y192.04%
Revenue Next 5Y151.48%

3.3 Evolution

KURA Yearly Revenue VS EstimatesKURA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B
KURA Yearly EPS VS EstimatesKURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

KURA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KURA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KURA Price Earnings VS Forward Price EarningsKURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, KURA is valued cheaply inside the industry as 99.26% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 6.39
EV/EBITDA N/A
KURA Per share dataKURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

KURA's earnings are expected to decrease with -8.55% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.83%
EPS Next 3Y-8.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KURA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KURA ONCOLOGY INC

NASDAQ:KURA (9/26/2025, 8:06:16 PM)

After market: 8.8105 -0.24 (-2.65%)

9.05

+0.69 (+8.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners92.91%
Inst Owner Change2.88%
Ins Owners1.18%
Ins Owner Change1.73%
Market Cap785.54M
Analysts84
Price Target27.54 (204.31%)
Short Float %9.91%
Short Ratio5.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-62.9%
Min EPS beat(2)-65.56%
Max EPS beat(2)-60.23%
EPS beat(4)2
Avg EPS beat(4)-14.58%
Min EPS beat(4)-65.56%
Max EPS beat(4)66.19%
EPS beat(8)5
Avg EPS beat(8)-5.36%
EPS beat(12)9
Avg EPS beat(12)-0.33%
EPS beat(16)13
Avg EPS beat(16)1.4%
Revenue beat(2)1
Avg Revenue beat(2)-23.89%
Min Revenue beat(2)-59.12%
Max Revenue beat(2)11.33%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.18%
PT rev (3m)4.18%
EPS NQ rev (1m)-0.27%
EPS NQ rev (3m)-19.02%
EPS NY rev (1m)0%
EPS NY rev (3m)-20.44%
Revenue NQ rev (1m)10%
Revenue NQ rev (3m)-67.23%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)-23.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.43
P/FCF 6.39
P/OCF 6.28
P/B 2.57
P/tB 2.57
EV/EBITDA N/A
EPS(TTM)-2.26
EYN/A
EPS(NY)-2.63
Fwd EYN/A
FCF(TTM)1.42
FCFY15.64%
OCF(TTM)1.44
OCFY15.91%
SpS0.96
BVpS3.52
TBVpS3.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.89%
ROE -64.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 147.53%
ROA(3y)-28.89%
ROA(5y)-24.99%
ROE(3y)-37.6%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.08
Debt/EBITDA N/A
Cap/Depr 241.96%
Cap/Sales 2.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.16
Quick Ratio 6.16
Altman-Z -0.9
F-Score6
WACC9.95%
ROIC/WACCN/A
Cap/Depr(3y)52.78%
Cap/Depr(5y)301.16%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.12%
EPS Next Y-27%
EPS Next 2Y-13.83%
EPS Next 3Y-8.55%
EPS Next 5Y24.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year895.54%
Revenue Next 2Y404.04%
Revenue Next 3Y192.04%
Revenue Next 5Y151.48%
EBIT growth 1Y-9.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.59%
EBIT Next 3Y-15.94%
EBIT Next 5Y2.08%
FCF growth 1Y212.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y214.64%
OCF growth 3YN/A
OCF growth 5YN/A